{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of CI were not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"11.1","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of CI was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"3.0","upperLimit":"NA","value":"5.1"},{"comment":"Upper limit of CI was not estimable due to insufficient number of events.","groupId":"OG002","lowerLimit":"3.2","upperLimit":"NA","value":"6.9"},{"comment":"Median and upper limit of CI were not estimable due to insufficient number of events.","groupId":"OG003","lowerLimit":"5.5","upperLimit":"NA","value":"NA"},{"comment":"Lower and upper limit of CI were not estimable due to insufficient number of events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"12.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the first dose date of study drug to the date of death from any cause. Analysis was done using KM estimate. Participants who have not died by the analysis data cutoff date were censored at their last date known to be alive or cutoff date, whichever is earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\\^7 autologous anti-BCMA CAR T cells on Day 0.","id":"OG000","title":"Dose Escalation: 3 x 10^7 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\\^8 autologous anti-BCMA CAR T cells on Day 0.","id":"OG001","title":"Dose Escalation: 1 x 10^8 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\\^8 autologous anti-BCMA CAR T cells on Day 0.","id":"OG002","title":"Dose Escalation: 3 x 10^8 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\\^9 autologous anti-BCMA CAR T cells on Day 0.","id":"OG003","title":"Dose Escalation: 1 x 10^9 KITE-585"},{"description":"RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min \\[Grade 2 chronic kidney disease\\]) received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 24 mg/m\\^2/day IV infusion for 3 days followed by single infusion of KITE-585 at a tolerable dose of 3 x 10\\^7 autologous anti-BCMA CAR T cells on Day 0.","id":"OG004","title":"Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585"}],"paramType":"MEDIAN","populationDescription":"Participants in the Safety Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"From KITE-585 infusion to date of data cutoff (maximum: 17.6 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}